Afatinib is a clinically useful kinase inhibitor approved for the treatment of non-small cell lung cancer. It is a potent and highly selective inhibitor of mutant and wild-type EGFR (IC50 = 0.5 nM) and HER2 (IC50 = 14 nM).
* VAT and and shipping costs not included. Errors and price changes excepted
